BEUDAMED
    FDA Adverse Event Other Summary report: N

    SYNVISC (HYLAN G-F 20) INJECTION

    MDR report key: 3096206 · Received April 25, 2013

    Report

    Report Number
    2246315-2013-00262
    Event Type
    Other
    Date Received
    April 25, 2013
    Date of Event
    May 29, 2001
    Report Date
    March 29, 2013
    Manufacturer
    GENZYME BIOSURGERY (RIDGEFIELD)
    Product Code
    MOZ
    PMA / PMN Number
    P940015
    Adverse Event
    Yes
    Report Source
    Manufacturer report
    Reporter Location
    US
    Reporter Occupation
    PHYSICIAN

    Narratives

    Additional Manufacturer Narrative · 1

    THE QA (QUALITY ASSURANCE) INVESTIGATION RESULTS WERE REC'D ON (B)(4) 2013. EVAL SUMMARY: THE PRODUCT LOT NUMBER WAS NOT PROVIDED; THEREFORE A BATCH RECORD REVIEW IS NOT POSSIBLE. IT IS THE REQUIREMENT TO REVIEW ALL FINISHED BATCH RECORDS FOR SPECIFICATION CONFORMANCE PRIOR TO RELEASE. ANY OUT OF SPECIFICATION RESULT IS IDENTIFIED AND MITIGATED. DATA IS PERIODICALLY PRESENTED AND REVIEWED BY INDIVIDUALS RESPONSIBLE FOR ASSURING PRODUCT QUALITY. THIS REVIEW HAS NOT INDICATED TRENDS THAT COULD BE ASSOCIATED WITH ANY PRODUCT COMPLAINT. GENZYME WILL CONTINUE TO MONITOR COMPLAINTS. MFR'S COMMENT: THIS CASE REPORT BELONGS TO A BATCH OF ICSRS FROM A DATABASE EXTRACTION CONTAINING A COLLECTION OF DATA FROM OCTOBER 1997 TO JULY 2010. THE BENEFIT RISK PROFILE OF THE PRODUCT IS NOT ALTERED BY THIS REPORT.

    Description of Event or Problem · 1

    SYNOVITIS, LEFT KNEE EFFUSION [JOINT EFFUSION]. CASE DESCRIPTION: SPONTANEOUS REPORT REC'D ON (B)(4) 2013 FROM A PHYSICIAN DATABASE EXTRACTION REGARDING A (B)(6) FEMALE PT, INITIALS UNK WITH OSTEOARTHRITIS (KELLGREN-LAWRENCE GRADE 1; NO PRIOR EFFUSION). THIS CASE BELONGS TO A BATCH OF ICSRS FROM A COMPANY PURCHASED DATABASE CONTAINING A COLLECTION OF DATA FROM OCT-1997 TO JUL-2010. THE PT'S MEDICAL HISTORY WAS NOT PROVIDED. ON (B)(6) 2001, THE PT INITIATED TREATMENT WITH FIRST COURSE OF INTRA-ARTICULAR INJECTION OF SYNVISC (HYLAN GF-20) IN LEFT KNEE (DOSAGE REGIMEN NOT PROVIDED). THE LOT NUMBER OF SYNVISC WAS NOT PROVIDED. ON (B)(6) 2001, THE PT EXPERIENCED SYNOVITIS OF LEFT KNEE. ON (B)(6) 2001 (14 DAYS LATER), THE PT DEVELOPED SECOND EPISODE OF SYNOVITIS. ON AN UNSPECIFIED DATE IN 2001, 22 CC OF CLEAR YELLOW JOINT FLUID WAS ASPIRATED FROM LEFT KNEE. THE PT REC'D TREATMENT WITH INTRAMUSCULAR CELESTONE (BETAMETHASONE) AT A DOSE OF 2 CC. AT THE TIME OF THE REPORT THE EVENT OF SYNOVITIS OF LEFT KNEE HAD NOT RECOVERED. THE OUTCOME OF LEFT KNEE EFFUSION WAS NOT PROVIDED. THE ACTION TAKEN WITH SYNVISC TREATMENT WAS NOT PROVIDED. RELEVANT CONCOMITANT WERE NOT PROVIDED. THE INTENSITY FOR THE EVENT OF SYNOVITIS AND LEFT KNEE EFFUSION WAS MILD. THE REPORTING PHYSICIAN ASSESSED THE RELATIONSHIP BETWEEN SYNVISC WITH SYNOVITIS AS DEFINITELY RELATED AND DID NOT PROVIDE A CAUSAL RELATIONSHIP WITH LEFT KNEE EFFUSION. F/U INFO WAS REC'D ON (B)(4) 2013 AND THE PT INITIALS WERE REPORTED AS (B)(6).

    Devices

    Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
    178967 SYNVISC (HYLAN G-F 20) INJECTION INTRA-ARTICULAR HYALURONIC ACID MOZ GENZYME BIOSURGERY (RIDGEFIELD) UNK UNK

    Patients

    Seq Age Sex Outcome Treatment
    1 42 YR Required Intervention